An anti-vascular endothelial growth factor (anti-VEGF) +  erlotinib combination has been investigated in patients with untreated, advanced, EGFR mutated NSCLC in the phase II JO25567 trial, which evaluated the efficacy of erlotinib and bevacizumab compared with erlotinib alone in patients with EGFR mutation-positive NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.